• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.95
  • VXN 18.04
  • VXO -
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

ThermoGenesis Corp. operates as a supplier of products targeting the worldwide adult stem cell market. It offers automated and semi-automated devices, and single-use processing disposables that enable the collection, processing, and cryopreservation of stem cells and other cellular tissues from cord blood and bone marrow used in the practice of regenerative medicine. Regenerative medicine is a field that aims to repair or restore lost or damaged tissue and cell function using cell-based therapies. The company?s core offerings include the AXP AutoXpress Platform for processing of cord blood; and BioArchive System, an automated cryogenic device used by cord blood banks for the cryopreservation and archiving of cord blood stem cell units for transplant. Its offerings also comprise MXP MarrowXpress, which is used for isolating stem cells from bone marrow, and the Res-Q 60 BMC, a point-of-care bone marrow stem cell processing system. In addition, ThermoGenesis markets the Thermoline product line, which includes the ultra-rapid plasma Thermoline Freezer and Thermoline Thawer. The company was founded in 1986 and is headquartered in Rancho Cordova, California.

NO
     
KOOL (Cesca Therapeutics Inc)
Last Trade 4.6671 Date 9/19/2019
Change % -0.70 % Price Change -0.04
Open 4.66 52 Week High 5.0999
High 4.85 52 Week Low 2.1
Low 4.66 Type stock
Volume 14115 Average Volume 236335
Prev Close 4.7 Stock Exchange NASDAQ
Bid 4.65 Ask 4.82
Bid Size 1 Ask Size 1
1st Yr Estimated EPS Growth -0.25 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 2.368 Book Value Yield 0.5038
Buy Back Yield CAPE Ratio
Cash Return -0.0308 Cash Flow per Share -1.5204
Cash Flow Yield -0.3235 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.017 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 0.5732 EV / Pre Tax Income
EV / Revenue 0.9305 EV / Total Asset 0.7356
Expected Dividend Growth Rate Free Cash Flow per Share -1.7329
Free Caash Flow Ratio Free Cash Flow Yield -0.3687
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0128 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 1.984758 PB Ratio 10 Year Growth 0.021224
PB Ratio 3 Year Growth 0.869607 Cash Ratio 3 Year Average 597.2474
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 5.888821
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.464174
Price to Cash Ratio 4.685142 Price / EBITDA
Price to Sales Ratio 0.896936 Price to Sales Ratio 10 Year Growth -0.068492
Price to Sales Ratio 3 Year Avg 1.01173 Price to Sales Ratio 5 Year Avg
Sale per Share 5.2401 Sales Yield 1.1149
Sustainable Growth Rate -1.6058 Tangible Book Value per Share 1.4112
Tangible Book Value per Share 3 year Avg 0.5261 Tangible Book Value per Share 5 year Avg 8.8296
Total Asset per Share 6.8418 Total Yield
Working Capital per Share 1.3963 Working Capital per Share 3 Year Avg 4.9626
Working Capital per Share 5 Year Avg 23.6796 Beta 1.548988